Le Lézard
Classified in: Environment, Health
Subjects: MAV, ENI

Media Advisory - Panel discussion on impact of climate change on health in Montreal this evening


OTTAWA, Nov. 18, 2019 /CNW/ - Tonight, the Canadian Medical Association (CMA), in collaboration with the Canadian Public Health Association (CPHA) and the Lancet, will host an interactive panel discussion on the impact of climate change and health.

The discussion follows the publication of the latest set of indicators by the Lancet Countdown on Health and Climate Change (published on Wednesday, November 13) and will feature lead author, Dr. Courtney Howard, CMA president Dr. Sandy Buchman, Dr. Claudel Pétrin-Desrosiers and Carol Devine from Médecins sans Frontières.

 

WHEN:

Monday, November 18 at 6:30 ? 8:30 p.m.



WHERE:

Centre for Sustainable Development


50, Sainte-Catherine Street West


Montreal, QC



WHAT:

Panel discussion on the Lancet Countdown Policy Brief: Canada in 2019



WHO:


Dr. Courtney Howard, Canadian Brief Lead Author
Dr. Sandy Buchman, CMA president
Dr. Claudel Pétrin-Desrosiers, CAPE
Carol Devine, Humanitarian Affairs Advisory, MSF

 

SOURCE Canadian Medical Association


These press releases may also interest you

at 16:32
The wishes that Make-A-Wish grants wouldn't be possible without the support of countless "WishMakers" such as donors, volunteers, corporate partners, community advocates and more. "WishMakers" ? a term for anyone who steps up to take action...

at 16:30
Today, the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, announced a new appointment to the Canadian Centre on Substance Use and Addiction (CCSA) Board of Directors. Scott Elliott is appointed as...

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...



News published on and distributed by: